Skip to main content
Top
Published in: Breast Cancer Research 1/2000

01-12-2001 | Paper Report

Cyclin D1in breast cancer is not associated with Ki67 but with ER

Author: George Skliris

Published in: Breast Cancer Research | Issue 1/2000

Login to get access

Excerpt

D-type cyclins are implicated in cell cycle regulation. The cyclin D1 gene is amplified in 15-20% of breast cancers while the protein is overexpressed in 50% of these cancers (see Additional information [1]). Overexpression of cyclin D1 has been linked with oestrogen receptor (ER)a, because it can stimulate transcriptional functions in the absence of oestrogen (see Additional information [2]). A negative association in normal breast has been reported for ERa and Ki67 (a proliferation marker), although this relationship changes in many precancerous and ER-positive cancers. Therefore, the aim of the study was to investigate the interaction between cyclin D1, ER and Ki67 in normal and malignant breast material. …
Literature
1.
go back to reference Shoker BS, Jarvis C, Davies MPA, Iqbal M, Sibson DR, Sloane JP: Immunodetectable cyclin D1is associated with oestrogen receptor but not Ki67 in normal, cancer and precancerous breast lesions. Br J Cancer . 2001, 84: 1064-1068. CrossRefPubMedPubMedCentral Shoker BS, Jarvis C, Davies MPA, Iqbal M, Sibson DR, Sloane JP: Immunodetectable cyclin D1is associated with oestrogen receptor but not Ki67 in normal, cancer and precancerous breast lesions. Br J Cancer . 2001, 84: 1064-1068. CrossRefPubMedPubMedCentral
Metadata
Title
Cyclin D1in breast cancer is not associated with Ki67 but with ER
Author
George Skliris
Publication date
01-12-2001
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue 1/2000
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr-2001-68466

Other articles of this Issue 1/2000

Breast Cancer Research 1/2000 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine